AstraZeneca grabs an FDA OK for its new leukemia drug, to be marketed as Lumoxiti

AstraZeneca grabs an FDA OK for its new leukemia drug, to be marketed as Lumoxiti

Submitted by admin on September 13, 2018 - 11:22pm
Source: 
Endpoints
News Tags: 
AstraZeneca
hairy cell leukemia
moxetumomab pasudotox
Headline: 
AstraZeneca grabs an FDA OK for its new leukemia drug, to be marketed as Lumoxiti
snippet: 

AstraZeneca $AZN just got another boost for its oncology portfolio. The FDA has whisked through a fast OK for the anti-CD22 drug moxetumomab pasudotox for rare cases of hairy cell leukemia.

Do Not Allow Advertisers to Use My Personal information